Drug policy and global regulatory capitalism: The case of new psychoactive substances (NPS)

Saved in:

Bibliographic Details
Main Author:	Seddon, T.
Format:	Journal Article
Language:	English
Subjects:	Acción contra las drogodependencias Drogas ilegales Drogas legales Drogodependencias Innovaciones Normativa Panorama internacional Adicciones Documental
Online Access:	DOI Path
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items: Drug policy and global regulatory capitalism: The case of new psychoactive substances (NPS)

Quick Look
New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors
Quick Look
Roadmaps to regulation: new psychoactive substances (NPS)
Quick Look
A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand
Quick Look
New psychoactive substances: Are there any good options for regulating new psychoactive substances?
Quick Look
Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill
Quick Look
Assessing the ‘added value’ of European policy on new psychoactive substances
Quick Look
New psychoactive substances and human enhancement drugs
Quick Look
New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe
Quick Look
Online test purchased new psychoactive substances in 5 different European countries: A snapshot study of chemical composition and price
Quick Look
Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, ‘legal highs’) in New Zealand
Quick Look
Motivations for new psychoactive substance use among regular psychostimulant users in Australia
Quick Look
I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances
Quick Look
EMCDDA–Europol Joint Report on a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (‘MT-45’)
Quick Look
EMCDDA-Europol Joint Report on a new psychoactive substance: 4,4'-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine)
Quick Look
Consideration of the novel psychoactive substances ('legal highs')
Quick Look
Health responses to new psychoactive substances
Quick Look
Global Smart Update 2015, vol. 14. Sección especial: Respuestas jurídicas a las NSP: múltiples enfoques aplicables a un problema complejo
Quick Look
Psychoactive Substances Bill
Quick Look
Next generation of novel psychoactive substances on the horizon. A complex problem to face
Quick Look
The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations
Quick Look
FROM POLICY ON ILLEGAL DRUGS TO A POLICY ON PSYCHOACTIVE SUBSTANCES
Quick Look
No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS)
Quick Look
Developing a vaccine against multiple psychoactive targets: a case study of heroin
Quick Look
A critical examination of the definition of ‘psychoactive effect’ in Australian drug legislation